Could a Sugar-Like substance shrink tumors? new study explores High-Dose FDG for advanced cancer
NCT ID NCT02130492
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether high doses of a radioactive sugar (FDG) can safely treat advanced cancers that no longer respond to standard therapies. FDG is taken up by cancer cells because they use a lot of glucose, and the radiation may kill them. The study involves 30 adults with stage IV solid tumors or lymphomas and monitors side effects and tumor shrinkage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Weill Medical College of Cornell University
New York, New York, 10024, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A lifeline for cancer caregivers: can simple phone support reduce their stress?
- A digital lifeline: could Real-Time symptom tracking transform care for kids with advanced cancer?
- Can a 30-hour e-learning course equip family doctors to deliver better palliative care?
- Can a new nucleotide analogue boost cancer treatment?
- Can a cancer vaccine train the body to fight advanced tumors?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?